Skip to main content
SinoMab BioScience Limited logo

SinoMab BioScience Limited — Investor Relations & Filings

Ticker · 3681 ISIN · HK0000544194 LEI · 9845009B6CEEC4694006 HKEX Manufacturing
Open in API
Filings indexed 319 across all filing types
Latest filing 2025-08-29 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 3681

About SinoMab BioScience Limited

http://www.sinomab.com

SinoMab BioScience Limited is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of therapeutic antibodies. The company focuses on developing novel, highly efficacious drugs, including "first-in-class" and "best-in-class" candidates, primarily for the treatment of immunological and life-threatening diseases, such as rheumatoid arthritis. SinoMab maintains full-spectrum drug development capabilities, covering antibody re-engineering, bioprocessing, and manufacturing, aimed at addressing significant unmet medical needs globally.

Recent filings

Filing Released Lang Actions
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025
Interim / Quarterly Report Classification · 95% confidence The document is an 'Interim Results Announcement' for SinoMab BioScience Limited for the six months ended 30 June 2025. It contains detailed financial highlights, business overviews, and management discussion regarding clinical trial progress. While it is an announcement, it provides substantive financial data and analysis for the interim period, fitting the definition of an Interim/Quarterly Report (IR) rather than a mere publication announcement (RPA). H1 2025
2025-08-29 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return under the Hong Kong Listing Rules (Main Board Rule 13.25A / GEM Rule 17.27A) detailing an issuance of new shares and changes in issued share capital. This is not a simple notification of publication or an AGM/annual report but a specific announcement of a capital change (new share issue). Therefore it falls under ‘Share Issue/Capital Change’ (SHA).
2025-08-29 English
COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 90% confidence The document is an announcement by SinoMab BioScience Limited regarding the completion of subscriptions for new shares under a general mandate, detailing the issuance of 24,965,400 new shares and the resulting effect on shareholding structure. This is a direct announcement of a new share issue and change in capital structure rather than a routine regulatory filing, dividend notice, or management change. Therefore, it best fits the category for share issuances and capital changes (SHA).
2025-08-29 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 85% confidence The text is a short announcement of a board meeting date to consider and approve the interim results and their publication. It does not include financial data itself or the report content, but simply notifies shareholders of the timing of the report approval. This matches the “Report Publication Announcement” category (RPA).
2025-08-18 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 90% confidence The document is a regulatory listing rules disclosure (Form FF305) under Hong Kong Stock Exchange rules, detailing changes in issued ordinary shares (issue of subscription shares) and treasury share balances. It is not an earnings release, call transcript, or AGM material, but a formal capital change notification. This matches the definition for Share Issue/Capital Change (Code: SHA).
2025-08-15 English
COMPLETION OF CERTAIN SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 90% confidence The document is an announcement by SinoMab BioScience Limited regarding the completion of subscriptions for new shares under its general mandate, detailing the issuance of 157,107,000 new shares, the use of proceeds, and the post-issuance shareholding structure. This falls under an announcement of a share issue/capital change rather than a financing report, regulatory filing, or other category. Therefore, it best matches the Share Issue/Capital Change category (SHA).
2025-08-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.